Investigate the safety and efficacy of small cell lung cancer,Kidney cancer and Primary liver cancer immunotherapy

Not Applicable

Conditions: Histopathologically confirmed small cell lung cancer (SCLC)
Histopathologically confirmed Kidney cancer
Histopathologically confirmed Liver cancer

Registration Number: ACTRN12618001337268

Lead Sponsor: The First Teaching Hospital, Inner Mongolia Medical University

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot yet recruiting

Sex: All

Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients, affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 8/10/2021

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 9/7/2020

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 6/25/2018

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 9/15/2020

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 8/10/2020

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 7/20/2020

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 1/24/2022

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 1/24/2022

A clinical trial to study Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII in Previously Untreated Patients with Severe Haemophilia A

CompletedPhase 3

Octapharma AG

Updated 11/24/2021

The ability to induce an immune response, efficacy and safety of treatment with Human-cl rhFVIII in previously Untreated Patients ,affected by inherited gender-related coagulation disorder ,in which affected males do not produce functional coagulation factor VIII (FVIII) in sufficient quantities to achieve satisfactory blood clotting.

Phase 1

OCTAPHARMA AG

Updated 12/10/2019

Clinical Trial Alerts

Stay informed of key developments in this trial with timely notifications for researchers and healthcare professionals.

Enrollment status and site changes

Protocol modifications and amendments

Outcome data and publication updates

Clinical Trial Alerts

Stay informed of key developments in this trial with timely notifications for researchers and healthcare professionals.

Enrollment status and site changes

Protocol modifications and amendments

Outcome data and publication updates

Home Terms & Conditions Privacy Policy